SCHEMBL155194

SCHEMBL155194

COc1ccc2ccsc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.48
CYP2A6 P11509 1/20 0.48
CA2 P00918 4/20 0.45
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
PDK1 Q15118 1/20 0.43
BACE1 P56817 1/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.42
PSMB8 P28062 1/20 0.42
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
MEN1 O00255 1/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31053115 1.00 CYP1A2 (0.48) CYP1A2CYP2A6CA2CYP3A4CYP2C19
SCHEMBL28744947 0.94 CA2 (0.45) CYP1A2CYP2A6CA2CYP3A4CYP2C19
SCHEMBL154909 0.83 BACE1 (0.52) CYP1A2CYP2A6CA2BACE1HSD17B1
SCHEMBL14609319 0.79 MRGPRX4 (0.42) CYP2A6CA2MRGPRX4SLC6A2SLC6A4
SCHEMBL28744573 0.79 CA2 (0.50) CYP1A2CYP2A6CA2BACE1MRGPRX4
SCHEMBL827314 0.79 PARP10 (0.44) CA2MRGPRX4POLBKMT2ACA12
SCHEMBL827195 0.79 MAPT (0.50) CYP1A2CA2CYP3A4CYP2C19MRGPRX4
SCHEMBL3794893 0.79 MRGPRX4 (0.40) CYP1A2CYP2A6CA2CYP3A4MRGPRX4
SCHEMBL15962630 0.76 CYP1A2 (0.46) CYP1A2CYP2A6CA2BACE1HSD17B1
SCHEMBL15495650 0.76 CA2 (0.52) CA2CYP3A4MRGPRX4POLBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813603-A Selective estrogen receptor alpha degradation compound and preparation method and application thereof 成都市第三人民医院 2023-09-29 CN claimed
CN-116704872-A Preparation method of surface-enhanced Raman label 南京工业大学 2023-09-05 CN claimed
EP-1644350-B1 SULFAMATE BENZOTHIOPHENE DERIVATIVES AS STEROID SULFATASE INHIBITORS THERAMEX (MC) 2009-07-01 EP claimed
US-7476691-B2 Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors LABORATOIRE THERAMEX (MC) 2009-01-13 US claimed
WO-2026090589-A1 HETEROCYCLIC HBS1L DEGRADERS TANGO THERAPEUTICS, INC. (US) 2026-04-30 WO disclosed
US-12497386-B2 Estrogen receptor-modulating compounds RADIUS PHARMACEUTICALS, INC. (US) 2025-12-16 US disclosed
US-12312324-B2 Fluorine-containing substituted benzothiophene compound, and pharmaceutical composition and application thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2025-05-27 US disclosed
US-20250084103-A1 COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-03-13 US disclosed
US-12180228-B2 Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-12-31 US disclosed
CN-116813603-B Selective estrogen receptor alpha degradation compound and preparation method and application thereof 成都市第三人民医院 2024-10-22 CN disclosed
US-20240308986-A1 ESTROGEN RECEPTOR-MODULATING COMPOUNDS RADIUS PHARMACEUTICALS, INC. 2024-09-19 US disclosed
US-12018019-B2 Estrogen receptor-modulating compounds RADIUS PHARMACEUTICALS, INC. (US) 2024-06-25 US disclosed
US-4788192-A TOPICALLY APPLYING; FOR GLAUCOMA MERCK & CO., INC. (US) 1988-11-29 US disclosed
EP-0145252-B1 INOTROPIC AGENTS ELI LILLY AND COMPANY (US) 1988-03-02 EP disclosed
US-4668697-A Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor MERCK & CO., INC. (US) 1987-05-26 US disclosed
US-4533734-A ANTICOAGULANTS, BRONCHODILATORS, VASODILATORS ELI LILLY AND COMPANY (US) 1985-08-06 US disclosed
EP-0145252-A1 Inotropic agents ELI LILLY AND COMPANY (US) 1985-06-19 EP disclosed
EP-0129478-A2 2-Sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1984-12-27 EP disclosed
EP-0017009-A2 Dyes and tints based on optionally substituted 2-amino-5-iminopyrrolenines BAYER AG (DE) 1980-10-15 EP disclosed
EP-0017012-A2 Dyes and process for the generation of tints based on optionally substituted 2-amino-5-iminopyrrolenines BAYER AG (DE) 1980-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240308986-A1 ESTROGEN RECEPTOR-MODULATING COMPOUNDS ESR2, GPER1, ESR1 CYP1A2 718/4885CYP2A6 352/4885CA2 2407/4885
US-12018019-B2 Estrogen receptor-modulating compounds ESR2, GPER1, ESR1 CYP1A2 718/4885CYP2A6 352/4885CA2 2407/4885
US-12312324-B2 Fluorine-containing substituted benzothiophene compound, and pharmaceutical composition and application thereof FLI1, ABCG2, AFF1 CYP1A2 310/4885CYP2A6 666/4885CA2 2878/4885
US-20250084103-A1 COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOF DNPEP, DHPS, NPEPPS CYP1A2 387/4885CYP2A6 578/4885CA2 4534/4885
US-12497386-B2 Estrogen receptor-modulating compounds ESR2, GPER1, ESR1 CYP1A2 718/4885CYP2A6 352/4885CA2 2407/4885
US-12180228-B2 Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof DNPEP, DHPS, NPEPPS CYP1A2 387/4885CYP2A6 578/4885CA2 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.